,address1,address2,city,state,zip,country,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,forwardPE,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,4-6 Bligh Street,Suite 12.01 Level 12,Sydney,NSW,2000,Australia,https://www.imugene.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc., as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.","{'maxAge': 1, 'name': 'Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD', 'age': 66, 'title': 'Exec. Chairman', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 350000, 'exercisedValue': 0, 'unexercisedValue': 0}",9,9,10,1,9,1693526400,1672444800,86400,4,0.061,0.062,0.06,0.066,0.061,0.062,0.06,0.066,0.0,2.411036,171072443,171072443,29119444,48558206,48558206,0.061,0.063,0,0,416889856,0.059,0.235,39.622894,0.08264,0.11889,0.0,0.0,AUD,239208192,Infinity,0.0,5256550978,6834259968,0.14779,0.091520004,6834259968,0.029,2.1034484,1688083200,1719705600,1688083200,-39171080,-0.01,0.0,1:7.5,1037059200,22.735,-6.21,-0.7227273,0.14113986,ASX,EQUITY,IMU.AX,IMU.AX,IMUGENE FPO,Imugene Limited,915145200,Australia/Sydney,AEST,0fda587c-084c-31fd-8068-3e1f0ea78fd9,finmb_11113368,36000000,0.061,0.54,0.21,0.42,0.51,2.0,buy,3,153150656,0.024,-38520656,553472,26.956,27.022,10521439,0.294,0.002,-0.14840999,-0.23952,10521439,-16185398,-31658512,-0.251,1.0,0.0,-3.87512,AUD,
1,4-6 Bligh Street,Suite 12.01 Level 12,Sydney,NSW,2000,Australia,https://www.imugene.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc., as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.","{'maxAge': 1, 'name': 'Ms. Leslie  Chong', 'title': 'CEO, MD & Exec. Director', 'fiscalYear': 2022, 'totalPay': 1066194, 'exercisedValue': 0, 'unexercisedValue': 0}",9,9,10,1,9,1693526400,1672444800,86400,4,0.061,0.062,0.06,0.066,0.061,0.062,0.06,0.066,0.0,2.411036,171072443,171072443,29119444,48558206,48558206,0.061,0.063,0,0,416889856,0.059,0.235,39.622894,0.08264,0.11889,0.0,0.0,AUD,239208192,Infinity,0.0,5256550978,6834259968,0.14779,0.091520004,6834259968,0.029,2.1034484,1688083200,1719705600,1688083200,-39171080,-0.01,0.0,1:7.5,1037059200,22.735,-6.21,-0.7227273,0.14113986,ASX,EQUITY,IMU.AX,IMU.AX,IMUGENE FPO,Imugene Limited,915145200,Australia/Sydney,AEST,0fda587c-084c-31fd-8068-3e1f0ea78fd9,finmb_11113368,36000000,0.061,0.54,0.21,0.42,0.51,2.0,buy,3,153150656,0.024,-38520656,553472,26.956,27.022,10521439,0.294,0.002,-0.14840999,-0.23952,10521439,-16185398,-31658512,-0.251,1.0,0.0,-3.87512,AUD,
2,4-6 Bligh Street,Suite 12.01 Level 12,Sydney,NSW,2000,Australia,https://www.imugene.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc., as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.","{'maxAge': 1, 'name': 'Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D.', 'title': 'Chief Technology Officer', 'fiscalYear': 2022, 'totalPay': 422977, 'exercisedValue': 0, 'unexercisedValue': 0}",9,9,10,1,9,1693526400,1672444800,86400,4,0.061,0.062,0.06,0.066,0.061,0.062,0.06,0.066,0.0,2.411036,171072443,171072443,29119444,48558206,48558206,0.061,0.063,0,0,416889856,0.059,0.235,39.622894,0.08264,0.11889,0.0,0.0,AUD,239208192,Infinity,0.0,5256550978,6834259968,0.14779,0.091520004,6834259968,0.029,2.1034484,1688083200,1719705600,1688083200,-39171080,-0.01,0.0,1:7.5,1037059200,22.735,-6.21,-0.7227273,0.14113986,ASX,EQUITY,IMU.AX,IMU.AX,IMUGENE FPO,Imugene Limited,915145200,Australia/Sydney,AEST,0fda587c-084c-31fd-8068-3e1f0ea78fd9,finmb_11113368,36000000,0.061,0.54,0.21,0.42,0.51,2.0,buy,3,153150656,0.024,-38520656,553472,26.956,27.022,10521439,0.294,0.002,-0.14840999,-0.23952,10521439,-16185398,-31658512,-0.251,1.0,0.0,-3.87512,AUD,
3,4-6 Bligh Street,Suite 12.01 Level 12,Sydney,NSW,2000,Australia,https://www.imugene.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc., as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.","{'maxAge': 1, 'name': 'Dr. Monil  Shah M.B.A., Pharm.D.', 'title': 'Chief Bus. Officer', 'fiscalYear': 2022, 'totalPay': 821742, 'exercisedValue': 0, 'unexercisedValue': 0}",9,9,10,1,9,1693526400,1672444800,86400,4,0.061,0.062,0.06,0.066,0.061,0.062,0.06,0.066,0.0,2.411036,171072443,171072443,29119444,48558206,48558206,0.061,0.063,0,0,416889856,0.059,0.235,39.622894,0.08264,0.11889,0.0,0.0,AUD,239208192,Infinity,0.0,5256550978,6834259968,0.14779,0.091520004,6834259968,0.029,2.1034484,1688083200,1719705600,1688083200,-39171080,-0.01,0.0,1:7.5,1037059200,22.735,-6.21,-0.7227273,0.14113986,ASX,EQUITY,IMU.AX,IMU.AX,IMUGENE FPO,Imugene Limited,915145200,Australia/Sydney,AEST,0fda587c-084c-31fd-8068-3e1f0ea78fd9,finmb_11113368,36000000,0.061,0.54,0.21,0.42,0.51,2.0,buy,3,153150656,0.024,-38520656,553472,26.956,27.022,10521439,0.294,0.002,-0.14840999,-0.23952,10521439,-16185398,-31658512,-0.251,1.0,0.0,-3.87512,AUD,
4,4-6 Bligh Street,Suite 12.01 Level 12,Sydney,NSW,2000,Australia,https://www.imugene.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc., as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.","{'maxAge': 1, 'name': 'Mr. Michael  Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD', 'age': 55, 'title': 'CFO & Company Sec.', 'yearBorn': 1967, 'exercisedValue': 0, 'unexercisedValue': 0}",9,9,10,1,9,1693526400,1672444800,86400,4,0.061,0.062,0.06,0.066,0.061,0.062,0.06,0.066,0.0,2.411036,171072443,171072443,29119444,48558206,48558206,0.061,0.063,0,0,416889856,0.059,0.235,39.622894,0.08264,0.11889,0.0,0.0,AUD,239208192,Infinity,0.0,5256550978,6834259968,0.14779,0.091520004,6834259968,0.029,2.1034484,1688083200,1719705600,1688083200,-39171080,-0.01,0.0,1:7.5,1037059200,22.735,-6.21,-0.7227273,0.14113986,ASX,EQUITY,IMU.AX,IMU.AX,IMUGENE FPO,Imugene Limited,915145200,Australia/Sydney,AEST,0fda587c-084c-31fd-8068-3e1f0ea78fd9,finmb_11113368,36000000,0.061,0.54,0.21,0.42,0.51,2.0,buy,3,153150656,0.024,-38520656,553472,26.956,27.022,10521439,0.294,0.002,-0.14840999,-0.23952,10521439,-16185398,-31658512,-0.251,1.0,0.0,-3.87512,AUD,
5,4-6 Bligh Street,Suite 12.01 Level 12,Sydney,NSW,2000,Australia,https://www.imugene.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc., as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.","{'maxAge': 1, 'name': 'Dr. Bradley  Glover Ph.D.', 'age': 53, 'title': 'Chief Operating Officer', 'yearBorn': 1969, 'exercisedValue': 0, 'unexercisedValue': 0}",9,9,10,1,9,1693526400,1672444800,86400,4,0.061,0.062,0.06,0.066,0.061,0.062,0.06,0.066,0.0,2.411036,171072443,171072443,29119444,48558206,48558206,0.061,0.063,0,0,416889856,0.059,0.235,39.622894,0.08264,0.11889,0.0,0.0,AUD,239208192,Infinity,0.0,5256550978,6834259968,0.14779,0.091520004,6834259968,0.029,2.1034484,1688083200,1719705600,1688083200,-39171080,-0.01,0.0,1:7.5,1037059200,22.735,-6.21,-0.7227273,0.14113986,ASX,EQUITY,IMU.AX,IMU.AX,IMUGENE FPO,Imugene Limited,915145200,Australia/Sydney,AEST,0fda587c-084c-31fd-8068-3e1f0ea78fd9,finmb_11113368,36000000,0.061,0.54,0.21,0.42,0.51,2.0,buy,3,153150656,0.024,-38520656,553472,26.956,27.022,10521439,0.294,0.002,-0.14840999,-0.23952,10521439,-16185398,-31658512,-0.251,1.0,0.0,-3.87512,AUD,
6,4-6 Bligh Street,Suite 12.01 Level 12,Sydney,NSW,2000,Australia,https://www.imugene.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc., as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.","{'maxAge': 1, 'name': 'Ms. Ursula  McCurry', 'title': 'Sr. VP of Clinical Operations', 'exercisedValue': 0, 'unexercisedValue': 0}",9,9,10,1,9,1693526400,1672444800,86400,4,0.061,0.062,0.06,0.066,0.061,0.062,0.06,0.066,0.0,2.411036,171072443,171072443,29119444,48558206,48558206,0.061,0.063,0,0,416889856,0.059,0.235,39.622894,0.08264,0.11889,0.0,0.0,AUD,239208192,Infinity,0.0,5256550978,6834259968,0.14779,0.091520004,6834259968,0.029,2.1034484,1688083200,1719705600,1688083200,-39171080,-0.01,0.0,1:7.5,1037059200,22.735,-6.21,-0.7227273,0.14113986,ASX,EQUITY,IMU.AX,IMU.AX,IMUGENE FPO,Imugene Limited,915145200,Australia/Sydney,AEST,0fda587c-084c-31fd-8068-3e1f0ea78fd9,finmb_11113368,36000000,0.061,0.54,0.21,0.42,0.51,2.0,buy,3,153150656,0.024,-38520656,553472,26.956,27.022,10521439,0.294,0.002,-0.14840999,-0.23952,10521439,-16185398,-31658512,-0.251,1.0,0.0,-3.87512,AUD,
7,4-6 Bligh Street,Suite 12.01 Level 12,Sydney,NSW,2000,Australia,https://www.imugene.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc., as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.","{'maxAge': 1, 'name': 'Dr. John  Byon', 'title': 'Sr. VP of Clinical Devel.', 'exercisedValue': 0, 'unexercisedValue': 0}",9,9,10,1,9,1693526400,1672444800,86400,4,0.061,0.062,0.06,0.066,0.061,0.062,0.06,0.066,0.0,2.411036,171072443,171072443,29119444,48558206,48558206,0.061,0.063,0,0,416889856,0.059,0.235,39.622894,0.08264,0.11889,0.0,0.0,AUD,239208192,Infinity,0.0,5256550978,6834259968,0.14779,0.091520004,6834259968,0.029,2.1034484,1688083200,1719705600,1688083200,-39171080,-0.01,0.0,1:7.5,1037059200,22.735,-6.21,-0.7227273,0.14113986,ASX,EQUITY,IMU.AX,IMU.AX,IMUGENE FPO,Imugene Limited,915145200,Australia/Sydney,AEST,0fda587c-084c-31fd-8068-3e1f0ea78fd9,finmb_11113368,36000000,0.061,0.54,0.21,0.42,0.51,2.0,buy,3,153150656,0.024,-38520656,553472,26.956,27.022,10521439,0.294,0.002,-0.14840999,-0.23952,10521439,-16185398,-31658512,-0.251,1.0,0.0,-3.87512,AUD,
8,4-6 Bligh Street,Suite 12.01 Level 12,Sydney,NSW,2000,Australia,https://www.imugene.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc., as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.","{'maxAge': 1, 'name': 'Dr. Joseph Paul Woodard Jr., M.D.', 'title': 'Chief Medical Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",9,9,10,1,9,1693526400,1672444800,86400,4,0.061,0.062,0.06,0.066,0.061,0.062,0.06,0.066,0.0,2.411036,171072443,171072443,29119444,48558206,48558206,0.061,0.063,0,0,416889856,0.059,0.235,39.622894,0.08264,0.11889,0.0,0.0,AUD,239208192,Infinity,0.0,5256550978,6834259968,0.14779,0.091520004,6834259968,0.029,2.1034484,1688083200,1719705600,1688083200,-39171080,-0.01,0.0,1:7.5,1037059200,22.735,-6.21,-0.7227273,0.14113986,ASX,EQUITY,IMU.AX,IMU.AX,IMUGENE FPO,Imugene Limited,915145200,Australia/Sydney,AEST,0fda587c-084c-31fd-8068-3e1f0ea78fd9,finmb_11113368,36000000,0.061,0.54,0.21,0.42,0.51,2.0,buy,3,153150656,0.024,-38520656,553472,26.956,27.022,10521439,0.294,0.002,-0.14840999,-0.23952,10521439,-16185398,-31658512,-0.251,1.0,0.0,-3.87512,AUD,
